A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis

Trial Profile

A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Pamrevlumab (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors FibroGen
  • Most Recent Events

    • 03 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 08 Nov 2016 According to FibroGen media release, data from open-label extension part, presented the 19th International Colloquium on Lung and Airway Fibrosis in September.
    • 10 Mar 2016 Results published in the European Respiratory Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top